Car-T: the first agreement for new therapies, based on actual results, is ready. Martini (Ex Dg Aifa): “A new negotiation model that puts Italy at the forefront”

The first agreement (with Novartis) for therapies that allow to reprogram some cells of the patient (the T lymphocytes), in order to make them able, once reinfused, to recognize and target the tumors, is approved by the CPR and CTS of Aifa. Now the agreement will have to be ratified by the AIFA Board and

Read More


CAR T cell therapies in pediatric oncology: access and future development by distributed academic cell manufacturing

Novel automation technologies enable the decentralized manufacturing of highly standardized CAR-T cell products in academic GMP facilities experienced with the production of patient-individual cell therapies. Dr Janet Rossig discusses the benefits of academic cell manufacturing, namely supporting the informed dissemination of CAR-T cell therapy to patients who benefit from this modality. She argues that this

Read More


Supercharging CAR-T with cancer vaccine, MIT team spotlights some new tech underpinning Darrell Irvine’s startup

Many of the efforts to improve on the first generation of CAR-T therapies such that they can reach solid tumors had focused on tweaks inherent to the cancer killing agent — specifically, utilizing more potent T cells as their base, from stem memory T cells to virally associated T cells to marrow infiltrating lymphocytes. But

Read More


Using CAR T-cell Therapy in Older Patients With Aggressive Lymphoma

Article Highlights CAR T-cell therapy is gaining traction in relapsed/refractory lymphoma in older patients with aggressive disease. As a result of prospective trials investigating CAR T-cell therapy, there is potential that older patients with lymphoma can be spared multiple lines of chemotherapy and its resultant toxicities while still having long-term clinical benefit. Toxicities are still

Read More


De-TOXing exhausted T cells may bolster CAR T immunotherapy against solid tumours

A decade ago researchers announced development of a cancer immunotherapy called CAR (for chimeric antigen receptor)-T, in which a patient is re-infused with their own genetically modified T cells equipped to mount a potent anti-tumour attack. Since then CAR T approaches (one of several strategies collectively known as “adoptive T cell transfer”) have made headlines

Read More


New tools for new treatments

Source Nature From antibiotics and organoids to CRISPR, improved biomedical methods and apparatus are enabling new therapies. Organoids Mini organs stand in for test models The term ‘organoid’ didn’t exist a decade ago. Now it’s a buzzword in biomedical science for a three-dimensional multi-cellular structure or ‘mini organ’. Thanks to advances with pluripotent stem cells

Read More